Plouin P F, Breart G, Maillard F, Papiernik E, Relier J P
Service d'Hypertension, Hôpital Broussais, Paris, France.
Br J Obstet Gynaecol. 1988 Sep;95(9):868-76. doi: 10.1111/j.1471-0528.1988.tb06571.x.
Labetalol was compared with methyldopa in a randomized controlled trial involving 176 pregnant women with mild to moderate hypertension. Diastolic blood pressure below 86 mmHg was obtained in a similar proportion of women given labetalol or methyldopa. Intrauterine death occurred in four women treated with methyldopa, and the one neonatal death on day 1 occurred in the labetalol group. The average birthweight and the proportion of preterm or small-for-gestational-age babies were similar in both groups. Heart rate, blood pressure, blood glucose, respiratory rate, and Silverman score of the babies did not differ between the two treatment groups, whether the comparison was made for all the infants, or only for those that were preterm or small-for-gestational-age. These data indicate that maternal beta-blockade with labetalol is as safe as methyldopa for the fetus and the newborn.
在一项涉及176名轻度至中度高血压孕妇的随机对照试验中，对拉贝洛尔和甲基多巴进行了比较。接受拉贝洛尔或甲基多巴治疗的女性中，舒张压低于86 mmHg的比例相似。接受甲基多巴治疗的4名女性发生了宫内死亡，拉贝洛尔组有1例新生儿在第1天死亡。两组的平均出生体重以及早产或小于胎龄儿的比例相似。无论对所有婴儿进行比较，还是仅对早产或小于胎龄的婴儿进行比较，两个治疗组婴儿的心率、血压、血糖、呼吸频率和西尔弗曼评分均无差异。这些数据表明，母亲使用拉贝洛尔进行β受体阻滞对胎儿和新生儿与甲基多巴一样安全。
